PositiveID announces distribution partnership with Liberator Medical Print E-mail
By Staff and Wire Reports   
Wednesday, 20 October 2010 09:11

PositiveID Corporation (Nasdaq:PSID) announced today that it has received an initial order of 15,000 iGlucose(TM) units from Liberator Medical Holdings, Inc. ("Liberator"). Liberator offers over 5,000 products to Medicare-eligible patient populations with chronic conditions requiring repeat-orders of maintenance supplies.

Scott R. Silverman, Chairman and CEO of PositiveID, said, "We are very pleased to announce this important distribution partner for our iGlucose product, Liberator Medical led by founder and CEO Mark Libratore. As experts in the use of a national direct-to-consumer advertising model that has fueled the growth of Liberator Medical, we believe Mr. Libratore and his team can help us rapidly grow the awareness and adoption of iGlucose."

Silverman's focus gives PositiveID some reasons for a rebound

Liberator Medical Information

In an interview with BioMedReports earlier in the week, Silverman said "What iGlucose does is communicate your blood sugar reading and the amount  of insulin a person has injected to a third party recipient that designated by the diabetic patient upon initial registration. That could be their son, daughter, parent or more importantly a physician who has that person's medical records and information.  It will provide accurate and live blood sugar and insuline injection reading rather than looking back three or four months when you go to your doctor. So we have three products in the pipeline, GlucoChip which is the RF product with the sensor on the end, EasyCheck which is the breath analysis product and this wireless communication product called iGlucose."

Silverman noted that the iGlucose device is closest to market at this point and that PSID is preparing to file a 510-K application for it. Liberator's order is subject to PositiveID having obtained all final regulatory clearances required to sell iGlucose in the United States.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter